What you need to know
- Clinical trials have shown that Lenacapavir, developed by US-based Gilead Sciences, is more than 99 per cent effective in preventing HIV infections among high-risk populations.
- The US government and the Global Fund are co-financing an advanced market commitment to make the drug accessible to up to two million people across high-burden countries by 2028.